1
|
Costoya-Sánchez A, Moscoso A, Sobrino T, Ruibal Á, Grothe MJ, Schöll M, Silva-Rodríguez J, Aguiar P. Partial volume correction in longitudinal tau PET studies: is it really needed? Neuroimage 2024; 289:120537. [PMID: 38367651 DOI: 10.1016/j.neuroimage.2024.120537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 02/07/2024] [Accepted: 02/08/2024] [Indexed: 02/19/2024] Open
Abstract
BACKGROUND [18F]flortaucipir (FTP) tau PET quantification is known to be affected by non-specific binding in off-target regions. Although partial volume correction (PVC) techniques partially account for this effect, their inclusion may also introduce noise and variability into the quantification process. While the impact of these effects has been studied in cross-sectional designs, the benefits and drawbacks of PVC on longitudinal FTP studies is still under scrutiny. The aim of this work was to study the performance of the most common PVC techniques for longitudinal FTP imaging. METHODS A cohort of 247 individuals from the Alzheimer's Disease Neuroimaging Initiative with concurrent baseline FTP-PET, amyloid-beta (Aβ) PET and structural MRI, as well as with follow-up FTP-PET and MRI were included in the study. FTP-PET scans were corrected for partial volume effects using Meltzer's, a simple and popular analytical PVC, and both the region-based voxel-wise (RBV) and the iterative Yang (iY) corrections. FTP SUVR values and their longitudinal rates of change were calculated for regions of interest (ROI) corresponding to Braak Areas I-VI, for a temporal meta-ROI and for regions typically displaying off-target FTP binding (caudate, putamen, pallidum, thalamus, choroid plexus, hemispheric white matter, cerebellar white matter, and cerebrospinal fluid). The longitudinal correlation between binding in off-target and target ROIs was analysed for the different PVCs. Additionally, group differences in longitudinal FTP SUVR rates of change between Aβ-negative (A-) and Aβ-positive (A+), and between cognitively unimpaired (CU) and cognitively impaired (CI) individuals, were studied. Finally, we compared the ability of different partial-volume-corrected baseline FTP SUVRs to predict longitudinal brain atrophy and cognitive decline. RESULTS Among off-target ROIs, hemispheric white matter showed the highest correlation with longitudinal FTP SUVR rates from cortical target ROIs (R2=0.28-0.82), with CSF coming in second (R2=0.28-0.42). Application of voxel-wise PVC techniques minimized this correlation, with RBV performing best (R2=0.00-0.07 for hemispheric white matter). PVC also increased group differences between CU and CI individuals in FTP SUVR rates of change across all target regions, with RBV again performing best (No PVC: Cohen's d = 0.26-0.66; RBV: Cohen's d = 0.43-0.74). These improvements were not observed for differentiating A- from A+ groups. Additionally, voxel-wise PVC techniques strengthened the correlation between baseline FTP SUVR and longitudinal grey matter atrophy and cognitive decline. CONCLUSION Quantification of longitudinal FTP SUVR rates of change is affected by signal from off-target regions, especially the hemispheric white matter and the CSF. Voxel-wise PVC techniques significantly reduce this effect. PVC provided a significant but modest benefit for tasks involving the measurement of group-level longitudinal differences. These findings are particularly relevant for the estimations of sample sizes and analysis methodologies of longitudinal group studies.
Collapse
Affiliation(s)
- Alejandro Costoya-Sánchez
- Molecular Imaging Group. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Av. Barcelona SN, 15782, Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n, Santiago de Compostela, Spain
| | - Alexis Moscoso
- Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden
| | - Tomás Sobrino
- NeuroAging Laboratory Group (NEURAL), Clinical Neurosciences Research Laboratories (LINC), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital, Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain
| | - Álvaro Ruibal
- Molecular Imaging Group. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Av. Barcelona SN, 15782, Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n, Santiago de Compostela, Spain
| | - Michel J Grothe
- Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain; Reina Sofía Alzheimer's Centre, CIEN Foundation, ISCIII, Madrid, 28031, Spain
| | - Michael Schöll
- Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden; Dementia Research Centre, Institute of Neurology, University College London, London, United Kingdom
| | - Jesús Silva-Rodríguez
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain; Reina Sofía Alzheimer's Centre, CIEN Foundation, ISCIII, Madrid, 28031, Spain.
| | - Pablo Aguiar
- Molecular Imaging Group. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Av. Barcelona SN, 15782, Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n, Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
2
|
Neira S, Guiu-Souto J, Pais P, Rodríguez Martínez de Llano S, Fernández C, Pubul V, Ruibal Á, Pombar M, Gago-Arias A, Pardo-Montero J. Quantification of internal dosimetry in PET patients II: Individualized Monte Carlo-based dosimetry for [18F]fluorocholine PET. Med Phys 2021; 48:5448-5458. [PMID: 34260065 PMCID: PMC9291792 DOI: 10.1002/mp.15090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Revised: 06/04/2021] [Accepted: 06/28/2021] [Indexed: 12/03/2022] Open
Abstract
Purpose To obtain individualized internal doses with a Monte Carlo (MC) method in patients undergoing diagnostic [18F]FCH‐PET studies and to compare such doses with the MIRD method calculations. Methods A patient cohort of 17 males were imaged after intravenous administration of a mean [18F]FCH activity of 244.3 MBq. The resulting PET/CT images were processed in order to generate individualized input source and geometry files for dose computation with the MC tool GATE. The resulting dose estimates were studied and compared to the MIRD method with two different computational phantoms. Mass correction of the S‐factors was applied when possible. Potential sources of uncertainty were closely examined: the effect of partial body images, urinary bladder emptying, and biokinetic modeling. Results Large differences in doses between our methodology and the MIRD method were found, generally in the range ±25%, and up to ±120% for some cases. The mass scaling showed improvements, especially for non‐walled and high‐uptake tissues. Simulations of the urinary bladder emptying showed negligible effects on doses to other organs, with the exception of the prostate. Dosimetry based on partial PET/CT images (excluding the legs) resulted in an overestimation of mean doses to bone, skin, and remaining tissues, and minor differences in other organs/tissues. Estimated uncertainties associated with the biokinetics of FCH introduce variations of cumulated activities in the range of ±10% in the high‐uptake organs. Conclusions The MC methodology allows for a higher degree of dosimetry individualization than the MIRD methodology, which in some cases leads to important differences in dose values. Dosimetry of FCH‐PET based on a single partial PET study seems viable due to the particular biokinetics of FCH, even though some correction factors may need to be applied to estimate mean skin/bone doses.
Collapse
Affiliation(s)
- Sara Neira
- Group of Medical Physics and Biomathematics, Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, Spain
| | - Jacobo Guiu-Souto
- Department of Medical Physics, Centro Oncolóxico de Galicia, A Coruña, Spain
| | - Paulino Pais
- Department of Nuclear Medicine, Centro Oncolóxico de Galicia, A Coruña, Spain
| | | | - Carlos Fernández
- Department of Medical Physics, Centro Oncolóxico de Galicia, A Coruña, Spain
| | - Virginia Pubul
- Department of Nuclear Medicine, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - Álvaro Ruibal
- Department of Nuclear Medicine, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.,Group of Molecular Imaging and Oncology, Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, Spain.,Molecular Imaging Group, Department of Radiology, Faculty of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.,Fundación Tejerina, Madrid, Spain
| | - Miguel Pombar
- Group of Molecular Imaging and Oncology, Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, Spain.,Department of Medical Physics, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - Araceli Gago-Arias
- Group of Medical Physics and Biomathematics, Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, Spain.,Department of Medical Physics, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.,Institute of Physics, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Juan Pardo-Montero
- Group of Medical Physics and Biomathematics, Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, Spain.,Department of Medical Physics, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| |
Collapse
|
3
|
Paredes-Pacheco J, López-González FJ, Silva-Rodríguez J, Efthimiou N, Niñerola-Baizán A, Ruibal Á, Roé-Vellvé N, Aguiar P. SimPET-An open online platform for the Monte Carlo simulation of realistic brain PET data. Validation for 18 F-FDG scans. Med Phys 2021; 48:2482-2493. [PMID: 33713354 PMCID: PMC8252452 DOI: 10.1002/mp.14838] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Revised: 03/03/2021] [Accepted: 03/04/2021] [Indexed: 12/11/2022] Open
Abstract
Purpose SimPET (www.sim‐pet.org) is a free cloud‐based platform for the generation of realistic brain positron emission tomography (PET) data. In this work, we introduce the key features of the platform. In addition, we validate the platform by performing a comparison between simulated healthy brain FDG‐PET images and real healthy subject data for three commercial scanners (GE Advance NXi, GE Discovery ST, and Siemens Biograph mCT). Methods The platform provides a graphical user interface to a set of automatic scripts taking care of the code execution for the phantom generation, simulation (SimSET), and tomographic image reconstruction (STIR). We characterize the performance using activity and attenuation maps derived from PET/CT and MRI data of 25 healthy subjects acquired with a GE Discovery ST. We then use the created maps to generate synthetic data for the GE Discovery ST, the GE Advance NXi, and the Siemens Biograph mCT. The validation was carried out by evaluating Bland‐Altman differences between real and simulated images for each scanner. In addition, SPM voxel‐wise comparison was performed to highlight regional differences. Examples for amyloid PET and for the generation of ground‐truth pathological patients are included. Results The platform can be efficiently used for generating realistic simulated FDG‐PET images in a reasonable amount of time. The validation showed small differences between SimPET and acquired FDG‐PET images, with errors below 10% for 98.09% (GE Discovery ST), 95.09% (GE Advance NXi), and 91.35% (Siemens Biograph mCT) of the voxels. Nevertheless, our SPM analysis showed significant regional differences between the simulated images and real healthy patients, and thus, the use of the platform for converting control subject databases between different scanners requires further investigation. Conclusions The presented platform can potentially allow scientists in clinical and research settings to perform MC simulation experiments without the need for high‐end hardware or advanced computing knowledge and in a reasonable amount of time.
Collapse
Affiliation(s)
- José Paredes-Pacheco
- Radiology and Psychiatry Department, Faculty of Medicine, Universidade de Santiago de Compostela, Galicia, Spain.,Molecular Imaging Unit, Centro de Investigaciones Médico-Sanitarias, General Foundation of the University of Málaga, Málaga, Spain
| | - Francisco Javier López-González
- Radiology and Psychiatry Department, Faculty of Medicine, Universidade de Santiago de Compostela, Galicia, Spain.,Molecular Imaging Unit, Centro de Investigaciones Médico-Sanitarias, General Foundation of the University of Málaga, Málaga, Spain
| | - Jesús Silva-Rodríguez
- Nuclear Medicine Department & Molecular Imaging Research Group, University Hospital (SERGAS) & Health Research Institute of Santiago de Compostela (IDIS), Galicia, Spain.,R&D Department, Qubiotech Health Intelligence SL, A Coruña, Galicia, Spain
| | - Nikos Efthimiou
- Positron Emission Tomography Research Centre, University of Hull, Hull, HU6 7RX, UK
| | - Aida Niñerola-Baizán
- Nuclear Medicine Department, Hospital Clinic Barcelona, Universitat de Barcelona, Barcelona, Spain.,Biomedical Research Networking Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain
| | - Álvaro Ruibal
- Radiology and Psychiatry Department, Faculty of Medicine, Universidade de Santiago de Compostela, Galicia, Spain.,Nuclear Medicine Department & Molecular Imaging Research Group, University Hospital (SERGAS) & Health Research Institute of Santiago de Compostela (IDIS), Galicia, Spain
| | - Núria Roé-Vellvé
- Biomedical Research Networking Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain
| | - Pablo Aguiar
- Radiology and Psychiatry Department, Faculty of Medicine, Universidade de Santiago de Compostela, Galicia, Spain.,Nuclear Medicine Department & Molecular Imaging Research Group, University Hospital (SERGAS) & Health Research Institute of Santiago de Compostela (IDIS), Galicia, Spain
| |
Collapse
|
4
|
Gómez-Lado N, López-Arias E, Iglesias-Rey R, Díaz-Platas L, Medín-Aguerre S, Fernández-Ferreiro A, Posado-Fernández A, García-Varela L, Rodríguez-Pérez M, Campos F, Del Pino P, Ruibal Á, Pardo-Montero J, Castillo J, Aguiar P, Sobrino T. [ 18F]-FMISO PET/MRI Imaging Shows Ischemic Tissue around Hematoma in Intracerebral Hemorrhage. Mol Pharm 2020; 17:4667-4675. [PMID: 33186043 DOI: 10.1021/acs.molpharmaceut.0c00932] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Intracerebral hemorrhage (ICH), being the most severe cerebrovascular disease, accounts for 10-15% of all strokes. Hematoma expansion is one of the most important factors associated with poor outcome in intracerebral hemorrhage (ICH). Several studies have suggested that an "ischemic penumbra" might arise when the hematoma has a large expansion, but clinical studies are inconclusive. We performed a preclinical study to demonstrate the presence of hypoxic-ischemic tissue around the hematoma by means of longitudinal [18F]-fluoromisonidazole ([18F]-FMISO) PET/MRI studies over time in an experimental ICH model. Our results showed that all [18F]-FMISO PET/MRI images exhibited hypoxic-ischemic tissue around the hematoma area. A significant increase of [18F]-FMISO uptake was found at 18-24 h post-ICH when the maximum of hematoma volume is achieved and this increase disappeared before 42 h. These results demonstrate the presence of hypoxic tissue around the hematoma and open the possibility of new therapies aimed to reduce ischemic damage associated with ICH.
Collapse
Affiliation(s)
- Noemí Gómez-Lado
- Molecular Imaging Research Group, Nuclear Medicine Department, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain.,Molecular Imaging and Medical Physics Group, Psychiatry, Radiology, Public Health, Nursing and Medicine Department, University of Santiago de Compostela (USC), University Clinical Hospital, Santiago de Compostela 15706, Spain
| | - Esteban López-Arias
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - Ramón Iglesias-Rey
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - Lucía Díaz-Platas
- Galician PET Radiopharmacy Unit, GALARIA, University Clinical Hospital, Santiago de Compostela 15706, Spain
| | - Santiago Medín-Aguerre
- Galician PET Radiopharmacy Unit, GALARIA, University Clinical Hospital, Santiago de Compostela 15706, Spain
| | - Anxo Fernández-Ferreiro
- Pharmacology Group, Pharmacy Department, University Clinical Hospital, University of Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - Adrián Posado-Fernández
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - Lara García-Varela
- Molecular Imaging Research Group, Nuclear Medicine Department, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - Manuel Rodríguez-Pérez
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - Francisco Campos
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - Pablo Del Pino
- Center for Research in Biological Chemistry and Molecular Materials (CIQUS), Particle Physics Departament, University of Santiago de Compostela, Santiago de Compostela 15706, Spain
| | - Álvaro Ruibal
- Molecular Imaging Research Group, Nuclear Medicine Department, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain.,Molecular Imaging and Medical Physics Group, Psychiatry, Radiology, Public Health, Nursing and Medicine Department, University of Santiago de Compostela (USC), University Clinical Hospital, Santiago de Compostela 15706, Spain
| | - Juan Pardo-Montero
- Group of Medical Physics and Biomathematics, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - José Castillo
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - Pablo Aguiar
- Molecular Imaging Research Group, Nuclear Medicine Department, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain.,Molecular Imaging and Medical Physics Group, Psychiatry, Radiology, Public Health, Nursing and Medicine Department, University of Santiago de Compostela (USC), University Clinical Hospital, Santiago de Compostela 15706, Spain
| | - Tomás Sobrino
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| |
Collapse
|
5
|
Seoane-Viaño I, Gómez-Lado N, Lázare-Iglesias H, García-Otero X, Antúnez-López JR, Ruibal Á, Varela-Correa JJ, Aguiar P, Basit AW, Otero-Espinar FJ, González-Barcia M, Goyanes A, Luzardo-Álvarez A, Fernández-Ferreiro A. 3D Printed Tacrolimus Rectal Formulations Ameliorate Colitis in an Experimental Animal Model of Inflammatory Bowel Disease. Biomedicines 2020; 8:E563. [PMID: 33276641 PMCID: PMC7761558 DOI: 10.3390/biomedicines8120563] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Revised: 11/24/2020] [Accepted: 11/27/2020] [Indexed: 12/11/2022] Open
Abstract
The aim of this study was to fabricate novel self-supporting tacrolimus suppositories using semisolid extrusion 3-dimensional printing (3DP) and to investigate their efficacy in an experimental model of inflammatory bowel disease. Blends of Gelucire 44/14 and coconut oil were employed as lipid excipients to obtain suppository formulations with self-emulsifying properties, which were then tested in a TNBS (2,4,6-trinitrobenzenesulfonic acid) induced rat colitis model. Disease activity was monitored using PET/CT medical imaging; maximum standardized uptake values (SUVmax), a measure of tissue radiotracer accumulation rate, together with body weight changes and histological assessments, were used as inflammatory indices to monitor treatment efficacy. Following tacrolimus treatment, a significant reduction in SUVmax was observed on days 7 and 10 in the rat colon sections compared to non-treated animals. Histological analysis using Nancy index confirmed disease remission. Moreover, statistical analysis showed a positive correlation (R2 = 71.48%) between SUVmax values and weight changes over time. Overall, this study demonstrates the effectiveness of 3D printed tacrolimus suppositories to ameliorate colitis and highlights the utility of non-invasive PET/CT imaging to evaluate new therapies in the preclinical area.
Collapse
Affiliation(s)
- Iria Seoane-Viaño
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; (I.S.-V.); (X.G.-O.); (F.J.O.-E.)
- Paraquasil Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
| | - Noemí Gómez-Lado
- Nuclear Medicine Department and Molecular Imaging Group, University Clinical Hospital (CHUS) and Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (N.G.-L.); (Á.R.); (P.A.)
| | - Héctor Lázare-Iglesias
- Pathology Department, University Clinical Hospital Santiago de Compostela (SERGAS) (CHUS), 15706 Santiago de Compostela, Spain; (H.L.-I.); (J.R.A.-L.)
| | - Xurxo García-Otero
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; (I.S.-V.); (X.G.-O.); (F.J.O.-E.)
- Nuclear Medicine Department and Molecular Imaging Group, University Clinical Hospital (CHUS) and Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (N.G.-L.); (Á.R.); (P.A.)
| | - José Ramón Antúnez-López
- Pathology Department, University Clinical Hospital Santiago de Compostela (SERGAS) (CHUS), 15706 Santiago de Compostela, Spain; (H.L.-I.); (J.R.A.-L.)
| | - Álvaro Ruibal
- Nuclear Medicine Department and Molecular Imaging Group, University Clinical Hospital (CHUS) and Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (N.G.-L.); (Á.R.); (P.A.)
- Tejerina Foundation, José Abascal 40, 28003 Madrid, Spain
| | - Juan Jesús Varela-Correa
- Pharmacy Department, University Hospital Ourense (SERGAS), Calle Ramón Puga Noguerol 54, 32005 Ourense, Spain;
| | - Pablo Aguiar
- Nuclear Medicine Department and Molecular Imaging Group, University Clinical Hospital (CHUS) and Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain; (N.G.-L.); (Á.R.); (P.A.)
| | - Abdul W. Basit
- FabRx Ltd., 3 Romney Road, Ashford, Kent TN24 0RW, UK;
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
| | - Francisco J. Otero-Espinar
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; (I.S.-V.); (X.G.-O.); (F.J.O.-E.)
- Paraquasil Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
| | - Miguel González-Barcia
- Pharmacy Department, University Clinical Hospital Santiago de Compostela (SERGAS) (CHUS), 15706 Santiago de Compostela, Spain;
| | - Alvaro Goyanes
- FabRx Ltd., 3 Romney Road, Ashford, Kent TN24 0RW, UK;
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma Group (GI-1645), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Asteria Luzardo-Álvarez
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain; (I.S.-V.); (X.G.-O.); (F.J.O.-E.)
- Paraquasil Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
| | - Anxo Fernández-Ferreiro
- Pharmacy Department, University Clinical Hospital Santiago de Compostela (SERGAS) (CHUS), 15706 Santiago de Compostela, Spain;
- Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain
| |
Collapse
|
6
|
Neira S, Guiu‐Souto J, Díaz‐Botana P, Pais P, Fernández C, Pubul V, Ruibal Á, Candela‐Juan C, Gago‐Arias A, Pombar M, Pardo‐Montero J. Quantification of internal dosimetry in PET patients: individualized Monte Carlo vs generic phantom-based calculations. Med Phys 2020; 47:4574-4588. [PMID: 32569389 PMCID: PMC7586975 DOI: 10.1002/mp.14344] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 06/11/2020] [Accepted: 06/12/2020] [Indexed: 12/15/2022] Open
Abstract
PURPOSE The purpose of this work is to calculate individualized dose distributions in patients undergoing 18 F-FDG PET/CT studies through a methodology based on full Monte Carlo (MC) simulations and PET/CT patient images, and to compare such values with those obtained by employing nonindividualized phantom-based methods. METHODS We developed a MC-based methodology for individualized internal dose calculations, which relies on CT images (for organ segmentation and dose deposition), PET images (for organ segmentation and distributions of activities), and a biokinetic model (which works with information provided by PET and CT images) to obtain cumulated activities. The software vGATE version 8.1. was employed to carry out the Monte Carlo calculations. We also calculated deposited doses with nonindividualized phantom-based methods (Cristy-Eckerman, Stabin, and ICRP-133). RESULTS Median MC-calculated dose/activity values are within 0.01-0.03 mGy/MBq for most organs, with higher doses delivered especially to the bladder wall, major vessels, and brain (medians of 0.058, 0.060, 0.066 mGy/MBq, respectively). Comparison with values obtained with nonindividualized phantom-based methods has shown important differences in many cases (ranging from -80% to + 260%). These differences are significant (p < 0.05) for several organs/tissues, namely, remaining tissues, adrenals, bladder wall, bones, upper large intestine, heart, pancreas, skin, and stomach wall. CONCLUSIONS The methodology presented in this work is a viable and useful method to calculate internal dose distributions in patients undergoing medical procedures involving radiopharmaceuticals, individually, with higher accuracy than phantom-based methods, fulfilling the guidelines provided by the European Council directive 2013/59/Euratom.
Collapse
Affiliation(s)
- Sara Neira
- Group of Medical Physics and BiomathematicsInstituto de Investigación Sanitaria de SantiagoTravesía Choupana s/nSantiago de Compostela15706Spain
| | - Jacobo Guiu‐Souto
- Department of Medical PhysicsCentro Oncolóxico de GaliciaC/ Doctor Camilo Beiras 1Coruña15009 ASpain
| | - Pablo Díaz‐Botana
- Group of Medical Physics and BiomathematicsInstituto de Investigación Sanitaria de SantiagoTravesía Choupana s/nSantiago de Compostela15706Spain
- Galician Supercomputation Center (CESGA)Avenida de Vigo s/nSantiago de Compostela15705Spain
| | - Paulino Pais
- Department of Nuclear MedicineCentro Oncolóxico de GaliciaC/ Doctor Camilo Beiras 1Coruña15009 ASpain
| | - Carlos Fernández
- Department of Medical PhysicsCentro Oncolóxico de GaliciaC/ Doctor Camilo Beiras 1Coruña15009 ASpain
| | - Virginia Pubul
- Department of Nuclear MedicineComplexo Hospitalario Universitario de Santiago de CompostelaTravesía Choupana s/nSantiago de Compostela15706Spain
| | - Álvaro Ruibal
- Department of Nuclear MedicineComplexo Hospitalario Universitario de Santiago de CompostelaTravesía Choupana s/nSantiago de Compostela15706Spain
- Group of Molecular Imaging and OncologyInstituto de Investigación Sanitaria de Santiago, Travesía Choupana s/nSantiago de Compostela15706Spain
- Molecular Imaging GroupDepartment of RadiologyFaculty of MedicineUniversidade de Santiago de CompostelaCampus VidaSantiago de Compostela15782Spain
- Fundación TejerinaC/ José Abascal 40Madrid28003Spain
| | - Cristian Candela‐Juan
- Centro Nacional de DosimetríaInstituto Nacional de Gestión SanitariaAv. Campanar 21Valencia46009Spain
| | - Araceli Gago‐Arias
- Group of Medical Physics and BiomathematicsInstituto de Investigación Sanitaria de SantiagoTravesía Choupana s/nSantiago de Compostela15706Spain
- Instituto de FísicaPontificia Universidad Católica de ChileSantiagoChile
| | - Miguel Pombar
- Group of Molecular Imaging and OncologyInstituto de Investigación Sanitaria de Santiago, Travesía Choupana s/nSantiago de Compostela15706Spain
- Department of Medical PhysicsComplexo Hospitalario Universitario de Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706Spain
| | - Juan Pardo‐Montero
- Group of Medical Physics and BiomathematicsInstituto de Investigación Sanitaria de SantiagoTravesía Choupana s/nSantiago de Compostela15706Spain
- Department of Medical PhysicsComplexo Hospitalario Universitario de Santiago de CompostelaTravesía da Choupana s/nSantiago de Compostela15706Spain
| |
Collapse
|
7
|
López-González FJ, Silva-Rodríguez J, Paredes-Pacheco J, Niñerola-Baizán A, Efthimiou N, Martín-Martín C, Moscoso A, Ruibal Á, Roé-Vellvé N, Aguiar P. Intensity normalization methods in brain FDG-PET quantification. Neuroimage 2020; 222:117229. [PMID: 32771619 DOI: 10.1016/j.neuroimage.2020.117229] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 07/28/2020] [Accepted: 07/31/2020] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND The lack of standardization of intensity normalization methods and its unknown effect on the quantification output is recognized as a major drawback for the harmonization of brain FDG-PET quantification protocols. The aim of this work is the ground truth-based evaluation of different intensity normalization methods on brain FDG-PET quantification output. METHODS Realistic FDG-PET images were generated using Monte Carlo simulation from activity and attenuation maps directly derived from 25 healthy subjects (adding theoretical relative hypometabolisms on 6 regions of interest and for 5 hypometabolism levels). Single-subject statistical parametric mapping (SPM) was applied to compare each simulated FDG-PET image with a healthy database after intensity normalization based on reference regions methods such as the brain stem (RRBS), cerebellum (RRC) and the temporal lobe contralateral to the lesion (RRTL), and data-driven methods, such as proportional scaling (PS), histogram-based method (HN) and iterative versions of both methods (iPS and iHN). The performance of these methods was evaluated in terms of the recovery of the introduced theoretical hypometabolic pattern and the appearance of unspecific hypometabolic and hypermetabolic findings. RESULTS Detected hypometabolic patterns had significantly lower volumes than the introduced hypometabolisms for all intensity normalization methods particularly for slighter reductions in metabolism . Among the intensity normalization methods, RRC and HN provided the largest recovered hypometabolic volumes, while the RRBS showed the smallest recovery. In general, data-driven methods overcame reference regions and among them, the iterative methods overcame the non-iterative ones. Unspecific hypermetabolic volumes were similar for all methods, with the exception of PS, where it became a major limitation (up to 250 cm3) for extended and intense hypometabolism. On the other hand, unspecific hypometabolism was similar far all methods, and usually solved with appropriate clustering. CONCLUSIONS Our findings showed that the inappropriate use of intensity normalization methods can provide remarkable bias in the detected hypometabolism and it represents a serious concern in terms of false positives. Based on our findings, we recommend the use of histogram-based intensity normalization methods. Reference region methods performance was equivalent to data-driven methods only when the selected reference region is large and stable.
Collapse
Affiliation(s)
- Francisco J López-González
- Molecular Imaging Group, Radiology Department, Faculty of Medicine, Universidade de Santiago de Compostela, Galicia, Spain; Molecular Imaging Unit, Centro de Investigaciones Médico-Sanitarias, General Foundation of the University of Málaga, Málaga, Spain
| | - Jesús Silva-Rodríguez
- R&D Department, Qubiotech Health Intelligence, SL., Rúa Real n° 24, Planta 1, A Coruña, Galicia, Spain; Nuclear Medicine Department & Molecular Imaging Group, University Hospital (SERGAS) & Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana S/N 15706, Santiago de Compostela, Galicia, Spain.
| | - José Paredes-Pacheco
- Molecular Imaging Group, Radiology Department, Faculty of Medicine, Universidade de Santiago de Compostela, Galicia, Spain; Molecular Imaging Unit, Centro de Investigaciones Médico-Sanitarias, General Foundation of the University of Málaga, Málaga, Spain
| | - Aida Niñerola-Baizán
- Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain
| | - Nikos Efthimiou
- Positron Emission Tomography Research Centre, University of Hull, Hull HU6 7RX, United Kingdom
| | | | - Alexis Moscoso
- Molecular Imaging Group, Radiology Department, Faculty of Medicine, Universidade de Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department & Molecular Imaging Group, University Hospital (SERGAS) & Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana S/N 15706, Santiago de Compostela, Galicia, Spain
| | - Álvaro Ruibal
- Molecular Imaging Group, Radiology Department, Faculty of Medicine, Universidade de Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department & Molecular Imaging Group, University Hospital (SERGAS) & Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana S/N 15706, Santiago de Compostela, Galicia, Spain
| | - Núria Roé-Vellvé
- Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain
| | - Pablo Aguiar
- Molecular Imaging Group, Radiology Department, Faculty of Medicine, Universidade de Santiago de Compostela, Galicia, Spain; Nuclear Medicine Department & Molecular Imaging Group, University Hospital (SERGAS) & Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana S/N 15706, Santiago de Compostela, Galicia, Spain.
| |
Collapse
|
8
|
Luaces-Rodríguez A, Del Amo EM, Mondelo-García C, Gómez-Lado N, Gonzalez F, Ruibal Á, González-Barcia M, Zarra-Ferro I, Otero-Espinar FJ, Fernández-Ferreiro A, Aguiar P. PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats. Eur J Pharm Biopharm 2020; 154:330-337. [PMID: 32659326 DOI: 10.1016/j.ejpb.2020.06.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Revised: 06/26/2020] [Accepted: 06/29/2020] [Indexed: 12/23/2022]
Abstract
Intravitreal injections are the standard procedure in the treatment of retinal pathologies, such as the administration of the anti-VEGF antibodies in age-related macular degeneration. The aim of this study is to evaluate the intraocular and blood pharmacokinetics after an intravitreal injection of 89Zr-labelled bevacizumab and 89Zr-labelled aflibercept in Sprague-Dawley rats using Positron Emission Tomography. First, both antibodies were radiolabelled to zirconium-89 with a maximum specific activity of 15 Mbq/mg for bevacizumab and 10 Mbq/mg for aflibercept. Four µL containing 1-1.2 Mq of 89Zr-labelled compound were injected into the vitreous through a 35 G needle. A microPET acquisition was carried out immediately after the injection and at different time points through a 12-day study and blood samples were obtained through the tail vein. Radiolabelling was successfully performed with a radiochemical purity after ultrafiltration above 95% for both agents. Both antibodies ocular curves followed a two-compartment model in which an intraocular elimination half-life of 16.44 h was found for 89Zr-bevacizumab and 4.51 h for 89Zr-aflibercept, considering the alpha phase as the elimination phase. Regarding the beta phase, a half-life of 3.23 days for 89Zr-bevacizumab and 4.69 days for 89Zr-aflibercept were observed. With regards to blood concentration, 89Zr-bevacizumab showed a blood half-life of 7.08 days, whereas 89Zr-aflibercept's was 3.18 days, by a one-compartment model with first-order absorption kinetics. In conclusion, this study shows for the first time the ocular and blood pharmacokinetic analysis after intravitreal injection of aflibercept and bevacizumab in rats.
Collapse
Affiliation(s)
- Andrea Luaces-Rodríguez
- Pharmacology, Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain; Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Eva M Del Amo
- School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland
| | - Cristina Mondelo-García
- Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Noemí Gómez-Lado
- Nuclear Medicine Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain; Molecular Imaging Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Francisco Gonzalez
- Ophthalmology Department, University Clinical Hospital of Santiago de Compostela (SERGAS), CIMUS, University of Santiago de Compostela (USC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Álvaro Ruibal
- Nuclear Medicine Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain; Molecular Imaging Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Miguel González-Barcia
- Pharmacology, Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain; Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Irene Zarra-Ferro
- Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain
| | - Francisco J Otero-Espinar
- Pharmacology, Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Anxo Fernández-Ferreiro
- Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain.
| | - Pablo Aguiar
- Nuclear Medicine Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain; Molecular Imaging Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
| |
Collapse
|
9
|
Seoane-Viaño I, Gómez-Lado N, Lázare-Iglesias H, Rey-Bretal D, Lamela-Gómez I, Otero-Espinar FJ, Blanco-Méndez J, Antúnez-López JR, Pombo-Pasín M, Aguiar P, Ruibal Á, Luzardo-Álvarez A, Fernández-Ferreiro A. Evaluation of the therapeutic activity of melatonin and resveratrol in Inflammatory Bowel Disease: A longitudinal PET/CT study in an animal model. Int J Pharm 2019; 572:118713. [PMID: 31593809 DOI: 10.1016/j.ijpharm.2019.118713] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 09/13/2019] [Accepted: 09/16/2019] [Indexed: 12/29/2022]
Abstract
Inflammatory Bowel Disease (IBD) is a group of chronic disorders of the gastrointestinal tract, which two main types are Crohn's disease and ulcerative colitis. Although conventional therapeutic strategies have demonstrated to be effective in the IBD treatment, it is necessary to incorporate novel therapeutic agents that target other mechanisms involved in the pathogenesis of the disease, such as oxidative stress. For this reason, the efficacy in vivo of two antioxidant compounds, melatonin and resveratrol, has been investigated in an animal model of TNBS (2, 4, 6-trinitrobenzenesulfonic acid) induced colitis. PET/CT (Positron emission tomography/Computer Tomography) scans were performed to assess disease activity and evaluate treatment response. SUVmax (Standardized Uptake Value) values, body weight changes and histological evaluation were used as inflammatory indices to measure the efficacy of both treatments. SUVmax values increased rapidly after induction of colitis, but after the beginning of the treatment (day 3) a statistically significant decrease was observed on days 7 and 10 in treated animals compared to the non-treated group. This remission of the disease was also confirmed by histological analysis of the colon tissue using the Nancy histological index (p value < 0.05 for differences between non-treated and both groups of treated animals). Moreover, statistical analysis showed a correlation (R2 = 65.52%) between SUVmax values and weight changes throughout the treatment. Overall, this study demonstrates the potential of resveratrol, and melatonin in lower extent, as therapeutic agents in the IBD treatment.
Collapse
Affiliation(s)
- Iria Seoane-Viaño
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela Zip Code: 15782, Spain
| | - Noemí Gómez-Lado
- Nuclear Medicine Department and Molecular Imaging Group, University Clinical Hospital (CHUS) and Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela Zip Code: 15706, Spain
| | - Héctor Lázare-Iglesias
- Pathology Department, University Clinical Hospital Santiago de Compostela (SERGAS) (CHUS), Travesía da Choupana s/n, Santiago de Compostela Zip Code: 15706, Spain
| | - David Rey-Bretal
- Nuclear Medicine Department and Molecular Imaging Group, University Clinical Hospital (CHUS) and Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela Zip Code: 15706, Spain
| | - Iván Lamela-Gómez
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela Zip Code: 15782, Spain
| | - Francisco J Otero-Espinar
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela Zip Code: 15782, Spain
| | - José Blanco-Méndez
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela Zip Code: 15782, Spain
| | - José Ramón Antúnez-López
- Pathology Department, University Clinical Hospital Santiago de Compostela (SERGAS) (CHUS), Travesía da Choupana s/n, Santiago de Compostela Zip Code: 15706, Spain
| | - María Pombo-Pasín
- Nuclear Medicine Department and Molecular Imaging Group, University Clinical Hospital (CHUS) and Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela Zip Code: 15706, Spain
| | - Pablo Aguiar
- Nuclear Medicine Department and Molecular Imaging Group, University Clinical Hospital (CHUS) and Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela Zip Code: 15706, Spain; Molecular Imaging Group, Department of Psiquiatry, Radiology and Public Health, Faculty of Medicine, Universidade de Santiago de Compostela (USC), Santiago de Compostela Zip Code: 15782, Spain
| | - Álvaro Ruibal
- Nuclear Medicine Department and Molecular Imaging Group, University Clinical Hospital (CHUS) and Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela Zip Code: 15706, Spain; Molecular Imaging Group, Department of Psiquiatry, Radiology and Public Health, Faculty of Medicine, Universidade de Santiago de Compostela (USC), Santiago de Compostela Zip Code: 15782, Spain; Tejerina Foundation, José Abascal 40, Madrid Zip Code: 28003, Spain
| | - Asteria Luzardo-Álvarez
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela Zip Code: 15782, Spain.
| | - Anxo Fernández-Ferreiro
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela Zip Code: 15782, Spain; Pharmacy Department, University Clinical Hospital Santiago de Compostela (SERGAS) (CHUS), Travesía da Choupana s/n, Santiago de Compostela Zip Code: 15706, Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, Zip Code: 15706, Spain.
| |
Collapse
|
10
|
Moscoso A, Silva-Rodríguez J, Aldrey JM, Cortés J, Fernández-Ferreiro A, Gómez-Lado N, Ruibal Á, Aguiar P. Staging the cognitive continuum in prodromal Alzheimer's disease with episodic memory. Neurobiol Aging 2019; 84:1-8. [PMID: 31479859 DOI: 10.1016/j.neurobiolaging.2019.07.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 07/23/2019] [Accepted: 07/24/2019] [Indexed: 11/26/2022]
Abstract
It is unclear whether episodic memory is an appropriate descriptor of the cognitive continuum in mild cognitive impairment (MCI). Here, we investigated the ability of episodic memory to track cognitive changes in patients with MCI with biomarker evidence of Alzheimer's disease (AD). We examined 387 MCI amyloid-positive subjects, cognitively staged as "early" or "late" on the basis of episodic memory impairment. Cross-sectional and longitudinal comparisons between these 2 groups were performed for each amyloid, tau, and neurodegeneration (AT(N)) profile. Cross-sectional analyses indicate that "early" MCI represents a transitional phase between normal cognition and "late" MCI in the AD biomarker pathway. After adjusting by confounders and levels of A, T, and (N), "late" MCI progressed significantly faster than "early" MCI only in profiles with both abnormal amyloid and tau markers (A+T+(N)- p < 0.05, A+T+(N)+ p < 0.001). Episodic memory staging is useful for describing symptoms in prodromal AD and complements the AT(N) profiles. Our findings might have implications for the Numeric Clinical staging scheme of the National Institute on Aging and Alzheimer's Association research framework.
Collapse
Affiliation(s)
- Alexis Moscoso
- Nuclear Medicine Department and Molecular Imaging Group, University Hospital CHUS-IDIS, Santiago de Compostela, Spain
| | - Jesús Silva-Rodríguez
- Nuclear Medicine Department and Molecular Imaging Group, University Hospital CHUS-IDIS, Santiago de Compostela, Spain
| | - Jose Manuel Aldrey
- Neurology Department, University Hospital CHUS-IDIS, Santiago de Compostela, Spain
| | - Julia Cortés
- Nuclear Medicine Department and Molecular Imaging Group, University Hospital CHUS-IDIS, Santiago de Compostela, Spain
| | - Anxo Fernández-Ferreiro
- Pharmacy Department and Pharmacology group, University Hospital CHUS-IDIS, Santiago de Compostela, Spain
| | - Noemí Gómez-Lado
- Nuclear Medicine Department and Molecular Imaging Group, University Hospital CHUS-IDIS, Santiago de Compostela, Spain
| | - Álvaro Ruibal
- Nuclear Medicine Department and Molecular Imaging Group, University Hospital CHUS-IDIS, Santiago de Compostela, Spain; Department of Radiology, Molecular Imaging Group, Faculty of Medicine, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Spain; Fundación Tejerina, Madrid, Spain
| | - Pablo Aguiar
- Nuclear Medicine Department and Molecular Imaging Group, University Hospital CHUS-IDIS, Santiago de Compostela, Spain; Department of Radiology, Molecular Imaging Group, Faculty of Medicine, University of Santiago de Compostela (USC), Campus Vida, Santiago de Compostela, Spain.
| | | |
Collapse
|
11
|
Araújo-Vilar D, Domingo-Jiménez R, Ruibal Á, Aguiar P, Ibáñez-Micó S, Garrido-Pumar M, Martínez-Olmos MÁ, López-Soler C, Guillín-Amarelle C, González-Rodríguez M, Rodríguez-Núñez A, Álvarez-Escudero J, Liñares-Paz M, González-Méndez B, Rodríguez-García S, Sánchez-Iglesias S. Association of metreleptin treatment and dietary intervention with neurological outcomes in Celia's encephalopathy. Eur J Hum Genet 2018; 26:396-406. [PMID: 29367704 DOI: 10.1038/s41431-017-0052-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Revised: 11/03/2017] [Accepted: 11/13/2017] [Indexed: 12/18/2022] Open
Abstract
Celia's encephalopathy (progressive encephalopathy with/without lipodystrophy, PELD) is a recessive neurodegenerative disease that is fatal in childhood. It is caused by a c.985C>T variant in the BSCL2/seipin gene that results in an aberrant seipin protein. We evaluated neurological development before and during treatment with human recombinant leptin (metreleptin) plus a dietary intervention rich in polyunsaturated fatty acids (PUFA) in the only living patient. A 7 years and 10 months old girl affected by PELD was treated at age 3 years with metreleptin, adding at age 6 omega-3 fatty acid supplementation. Her mental age was evaluated using the Battelle Developmental Inventory Screening Test (BDI), and brain PET/MRI was performed before treatment and at age 5, 6.5, and 7.5 years. At age 7.5 years, the girl remains alive and leads a normal life for her mental age of 30 months, which increased by 4 months over the last 18 months according to BDI. PET images showed improved glucose uptake in the thalami, cerebellum, and brainstem. This patient showed a clear slowdown in neurological regression during leptin replacement plus a high PUFA diet. The aberrant BSCL2 transcript was overexpressed in SH-SY5Y cells and was treated with docosahexaenoic acid (200 µM) plus leptin (0.001 mg/ml) for 24 h. The relative expression of aberrant BSCL2 transcript was measured by qPCR. In vitro studies showed significant reduction (32%) in aberrant transcript expression. This therapeutic approach should be further studied in this devastating disease.
Collapse
Affiliation(s)
- David Araújo-Vilar
- Thyroid and Metabolic Diseases Unit, Biomedical Research Institute (CIMUS)-IDIS, School of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, Spain. .,Division of Endocrinology and Nutrition, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
| | - Rosario Domingo-Jiménez
- Section of Neuropediatrics, Division of Pediatrics, Hospital Clínico Universitario Virgen de la Arrixaca-IMIB Arrixaca, Murcia, Spain
| | - Álvaro Ruibal
- Division of Nuclear Medicine, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.,Fundación Tejerina, Madrid, Spain.,Molecular Imaging and Medical Physics, Universidade de Santiago de Compostela. IDIS, Santiago de Compostela, Spain
| | - Pablo Aguiar
- Division of Nuclear Medicine, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.,Molecular Imaging and Medical Physics, Universidade de Santiago de Compostela. IDIS, Santiago de Compostela, Spain
| | - Salvador Ibáñez-Micó
- Section of Neuropediatrics, Division of Pediatrics, Hospital Clínico Universitario Virgen de la Arrixaca-IMIB Arrixaca, Murcia, Spain
| | - Miguel Garrido-Pumar
- Division of Nuclear Medicine, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - Miguel Ángel Martínez-Olmos
- Division of Endocrinology and Nutrition, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | | | - Cristina Guillín-Amarelle
- Thyroid and Metabolic Diseases Unit, Biomedical Research Institute (CIMUS)-IDIS, School of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.,Division of Endocrinology and Nutrition, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - María González-Rodríguez
- Division of Endocrinology and Nutrition, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - Antonio Rodríguez-Núñez
- Pediatric Intensive Care Unit, Pediatric Area, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - Julián Álvarez-Escudero
- Anesthesia and Reanimation Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - Mercedes Liñares-Paz
- Department of Radiology, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - Blanca González-Méndez
- Thyroid and Metabolic Diseases Unit, Biomedical Research Institute (CIMUS)-IDIS, School of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Silvia Rodríguez-García
- Thyroid and Metabolic Diseases Unit, Biomedical Research Institute (CIMUS)-IDIS, School of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Sofía Sánchez-Iglesias
- Thyroid and Metabolic Diseases Unit, Biomedical Research Institute (CIMUS)-IDIS, School of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| |
Collapse
|
12
|
Moscoso A, Ruibal Á, Domínguez-Prado I, Fernández-Ferreiro A, Herranz M, Albaina L, Argibay S, Silva-Rodríguez J, Pardo-Montero J, Aguiar P. Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer. Eur J Nucl Med Mol Imaging 2017; 45:196-206. [DOI: 10.1007/s00259-017-3830-1] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Accepted: 09/04/2017] [Indexed: 01/28/2023]
|
13
|
Fernández-Ferreiro A, Luaces-Rodríguez A, Aguiar P, Pardo-Montero J, González-Barcia M, García-Varela L, Herranz M, Silva-Rodríguez J, Gil-Martínez M, Bermúdez MA, Vieites-Prado A, Blanco-Méndez J, Lamas MJ, Gómez-Ulla F, Ruibal Á, Otero-Espinar FJ, González F. Preclinical PET Study of Intravitreal Injections. Invest Ophthalmol Vis Sci 2017; 58:2843-2851. [PMID: 28570736 DOI: 10.1167/iovs.17-21812] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Purpose This work aimed at describing the time course of vitreous clearance through the use of positron emission tomography (PET) as a noninvasive tool for pharmacokinetic studies of intravitreal injection. Methods The pharmacokinetic profile of intravitreal injections of molecules labeled with 18Fluorine (18F) was evaluated in adult Sprague Dawley rats by using a dedicated small-animal PET/computed tomography scanner. Different conditions were studied: three molecules radiolabeled with 18F (18F-FDG, 18F-NaF, and 18F-Choline), three volumes of intravitreal injections (7, 4, and 2 μL), and absence or presence of eye inflammation (uveitis). Results Our results showed that there are significant pharmacokinetic differences among the radiolabeled molecules studied but not among the injected volumes. The presence or absence of uveitis was an important factor in vitreous clearance, since the elimination of the drug was clearly increased when this condition is present. Conclusions Intravitreal pharmacokinetic studies based on the use of dedicated PET imaging can be of potential interest as noninvasive tools in ophthalmic drug development in small animals.
Collapse
Affiliation(s)
- Anxo Fernández-Ferreiro
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain 2Pharmacy Department, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain 3Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 4Clinical Pharmacology Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Andrea Luaces-Rodríguez
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Pablo Aguiar
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 5Molecular Imaging Group, Department of Radiology, Faculty of Medicine, University of Santiago de Compostela, Spain
| | - Juan Pardo-Montero
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 6Medical Physics Department, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain
| | - Miguel González-Barcia
- Pharmacy Department, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain 4Clinical Pharmacology Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Lara García-Varela
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Michel Herranz
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 7Galician PET Radiopharmacy Unit, Galaria, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain
| | - Jesús Silva-Rodríguez
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - María Gil-Martínez
- Service of Ophthalmology, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - María A Bermúdez
- Department of Animal Biology, Vegetal Biology and Ecology, Faculty of Biology, University of A Coruña, A Coruña, Spain
| | - Alba Vieites-Prado
- Clinical Neurosciences Research Laboratory, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - José Blanco-Méndez
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - María Jesús Lamas
- Pharmacy Department, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain 4Clinical Pharmacology Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Francisco Gómez-Ulla
- Service of Ophthalmology, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 11Department of Surgery, University of Santiago de Compostela (CIMUS), Spain
| | - Álvaro Ruibal
- Molecular Imaging Group, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 5Molecular Imaging Group, Department of Radiology, Faculty of Medicine, University of Santiago de Compostela, Spain 12Nuclear Medicine Department, Complejo Hospitalario Universitario de Santiago (SERGAS), Santiago de Compostela, Spain
| | - Francisco Javier Otero-Espinar
- Department of Pharmacology, Pharmacy and Pharmaceutical Technology and Industrial Pharmacy Institute, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Francisco González
- Service of Ophthalmology, Complejo Hospitalario Universitario de Santiago (SERGAS), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain 11Department of Surgery, University of Santiago de Compostela (CIMUS), Spain
| |
Collapse
|
14
|
Silva-Rodríguez J, García-Varela L, López-Arias E, Domínguez-Prado I, Cortés J, Pardo-Montero J, Fernández-Ferreiro A, Ruibal Á, Sobrino T, Aguiar P. Impact of benzodiazepines on brain FDG-PET quantification after single-dose and chronic administration in rats. Nucl Med Biol 2016; 43:827-834. [DOI: 10.1016/j.nucmedbio.2016.09.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Revised: 09/02/2016] [Accepted: 09/07/2016] [Indexed: 02/08/2023]
|
15
|
Aguiar P, Pardo J, Arias M, Quintáns B, Fernández-Prieto M, Martínez-Regueiro R, Pumar JM, Silva-Rodríguez J, Ruibal Á, Sobrido MJ, Cortés J. PET and MRI detection of early and progressive neurodegeneration in spinocerebellar ataxia type 36. Mov Disord 2016; 32:264-273. [DOI: 10.1002/mds.26854] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2016] [Revised: 09/24/2016] [Accepted: 09/28/2016] [Indexed: 12/26/2022] Open
Affiliation(s)
- Pablo Aguiar
- Department of Nuclear Medicine and Molecular Imaging Group; University Hospital of Santiago de Compostela (CHUS), IDIS Health Research Institute; Santiago de Compostela Spain
- Department of Psychiatry, Radiology and Public Health; Universidade de Santiago de Compostela (USC); Santiago de Compostela Spain
| | - Julio Pardo
- Department of Psychiatry, Radiology and Public Health; Universidade de Santiago de Compostela (USC); Santiago de Compostela Spain
- Department of Neurology; University Hospital of Santiago de Compostela (CHUS); Santiago de Compostela Spain
- Neurogenetics research group; Instituto de Investigaciones Sanitarias de Santiago (IDIS); Santiago de Compostela Spain
| | - Manuel Arias
- Department of Psychiatry, Radiology and Public Health; Universidade de Santiago de Compostela (USC); Santiago de Compostela Spain
- Department of Neurology; University Hospital of Santiago de Compostela (CHUS); Santiago de Compostela Spain
- Neurogenetics research group; Instituto de Investigaciones Sanitarias de Santiago (IDIS); Santiago de Compostela Spain
| | - Beatriz Quintáns
- Neurogenetics research group; Instituto de Investigaciones Sanitarias de Santiago (IDIS); Santiago de Compostela Spain
- Genomic Medicine Group (U711), Centre for Biomedical Network Research on Rare Diseases (CIBERER); Institute of Health Carlos III; Madrid Spain
| | - Montse Fernández-Prieto
- Neurogenetics research group; Instituto de Investigaciones Sanitarias de Santiago (IDIS); Santiago de Compostela Spain
- Genomic Medicine Group (U711), Centre for Biomedical Network Research on Rare Diseases (CIBERER); Institute of Health Carlos III; Madrid Spain
| | - Rocío Martínez-Regueiro
- Neurogenetics research group; Instituto de Investigaciones Sanitarias de Santiago (IDIS); Santiago de Compostela Spain
- Department of Clinical Psychology and Psychobiology; Universidade de Santiago de Compostela (USC); Santiago de Compostela Spain
| | - José-Manuel Pumar
- Department of Psychiatry, Radiology and Public Health; Universidade de Santiago de Compostela (USC); Santiago de Compostela Spain
- Department of Radiology; University Hospital of Santiago de Compostela (CHUS); Santiago de Compostela Spain
| | - Jesús Silva-Rodríguez
- Department of Nuclear Medicine and Molecular Imaging Group; University Hospital of Santiago de Compostela (CHUS), IDIS Health Research Institute; Santiago de Compostela Spain
| | - Álvaro Ruibal
- Department of Nuclear Medicine and Molecular Imaging Group; University Hospital of Santiago de Compostela (CHUS), IDIS Health Research Institute; Santiago de Compostela Spain
- Department of Psychiatry, Radiology and Public Health; Universidade de Santiago de Compostela (USC); Santiago de Compostela Spain
| | - María-Jesús Sobrido
- Neurogenetics research group; Instituto de Investigaciones Sanitarias de Santiago (IDIS); Santiago de Compostela Spain
- Genomic Medicine Group (U711), Centre for Biomedical Network Research on Rare Diseases (CIBERER); Institute of Health Carlos III; Madrid Spain
| | - Julia Cortés
- Department of Nuclear Medicine and Molecular Imaging Group; University Hospital of Santiago de Compostela (CHUS), IDIS Health Research Institute; Santiago de Compostela Spain
- Department of Psychiatry, Radiology and Public Health; Universidade de Santiago de Compostela (USC); Santiago de Compostela Spain
| |
Collapse
|
16
|
Guiu-Souto J, Sánchez-García M, Vázquez-Vázquez R, Otero C, Luna V, Mosquera J, Busto RL, Aguiar P, Ruibal Á, Pardo-Montero J, Pombar-Cameán M. Evaluation and optimization of occupational eye lens dosimetry during positron emission tomography (PET) procedures. J Radiol Prot 2016; 36:299-308. [PMID: 27182832 DOI: 10.1088/0952-4746/36/2/299] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The last recommendations of the International Commission on Radiological Protection for eye lens dose suggest an important reduction on the radiation limits associated with early and late tissue reactions. The aim of this work is to quantify and optimize the eye lens dose associated to nurse staff during positron emission tomography (PET) procedures. PET is one of the most important diagnostic methods of oncological and neurological cancer disease involving an important number of workers exposed to the high energy isotope F-18. We characterize the relevant stages as preparation and administration of monodose syringes in terms of occupational dose. A direct reading silicon dosimeter was used to measure the lens dose to staff. The highest dose of radiation was observed during preparation of the fluorodesoxyglucose (FDG) syringes. By optimizing a suitable vials' distribution of FDG we find an important reduction in occupational doses. Extrapolation of our data to other clinical scenarios indicates that, depending on the work load and/or syringes activity, safety limits of the dose might be exceeded.
Collapse
Affiliation(s)
- Jacobo Guiu-Souto
- Department of Medical Physics and Radiological Protection, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Aguiar P, Pérez-Fentes D, Garrido M, García C, Ruibal Á, Cortés J. A method for estimating DMSA SPECT renal function for assessing the effect of percutaneous nephrolithotripsy on the treated pole. Q J Nucl Med Mol Imaging 2016; 60:154-162. [PMID: 27064495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
BACKGROUND The aim of this study was to develop a method for estimating DMSA SPECT renal function on each renal pole in order to evaluate the effect of percutaneous nephrolithotripsy by focusing the measurements on the region through which the percutaneous approach is performed. METHODS Twenty patients undergoing percutaneous nephrolithotripsy between November 2010 and June 2012 were included in this study. Both Planar and SPECT-DMSA studies were carried out before and after nephrolithotripsy. The effect of percutaneous nephrolithotripsy was evaluated by estimating the total renal function and the regional renal function of each renal pole. Despite PCNL has been previously reported as a minimally invasive technique, our results showed regional renal function decreases in the treated pole in most patients, affecting the total renal function in a few of them. RESULTS A quantification method was used for estimating the SPECT DMSA renal function of the upper, interpolar and lower renal poles. Our results confirmed that total renal function was preserved after nephrolithotripsy. Nevertheless, the proposed method showed that the regional renal function of the treated pole decreased in most patients (15 of 20 patients), allowing us to find differences in patients who had not shown changes in the total renal function obtained from conventional quantification methods. CONCLUSION A method for estimating the SPECT DMSA renal function focused on the treated pole enabled us to show for the first time that nephrolithotripsy can lead to a renal parenchymal damage restricted to the treated pole.
Collapse
Affiliation(s)
- Pablo Aguiar
- Nuclear Medicine Department, Clinical Hospital, Santiago de Compostela, Spain -
| | | | | | | | | | | |
Collapse
|
18
|
Gonzalez-Sistal A, Baltasar-Sánchez A, Menéndez P, Arias JI, Ruibal Á. Breastfeeding and Immunohistochemical Expression of ki-67, p53 and BCL2 in Infiltrating Lobular Breast Carcinoma. PLoS One 2016; 11:e0151093. [PMID: 26963620 PMCID: PMC4786125 DOI: 10.1371/journal.pone.0151093] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Accepted: 02/22/2016] [Indexed: 01/23/2023] Open
Abstract
Background/Aim Invasive lobular breast carcinoma is the second most common type of breast cancer after invasive ductal carcinoma. According to the American Cancer Society, more than 180,000 women in the United States find out they have invasive breast cancer each year. Personal history of breast cancer and certain changes in the breast are correlated with an increased breast cancer risk. The aim of this work was to analyze breastfeeding in patients with infiltrating lobular breast carcinoma, in relation with: 1) clinicopathological parameters, 2) hormonal receptors and 3) tissue-based tumor markers Materials and Methods The study included 80 women with ILC, 46 of which had breastfeed their children. Analyzed parameters were: age, tumor size, axillary lymph node (N), distant metastasis (M), histological grade (HG), estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), Ki-67, p53 and BCL2 Results ILC of non-lactating women showed a larger (p = 0.009), lymph node involvement (p = 0.051) and distant metastasis (p = 0.060). They were also more proliferative tumors measured by Ki-67 (p = 0.053). Breastfeeding history did not influence the subsequent behavior of the tumor regardless of histological subtype Conclusion Lactation seems to influence the biological characteristics of ILC defining a subgroup with more tumor size, axillary lymph node involvement, distant metastasis and higher proliferation measured by ki-67 expression.
Collapse
Affiliation(s)
- Angel Gonzalez-Sistal
- Department of Physiological Sciences II, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Alicia Baltasar-Sánchez
- Department of Physiological Sciences II, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | | | | | - Álvaro Ruibal
- Nuclear Medicine Service, Complejo Hospitalario Universitario, Faculty of Medicine, IDIS, Santiago de Compostela, Fundación Tejerina, Madrid, Spain
| |
Collapse
|
19
|
Silva-Rodríguez J, Tsoumpas C, Domínguez-Prado I, Pardo-Montero J, Ruibal Á, Aguiar P. Impact and correction of the bladder uptake on 18 F-FCH PET quantification: a simulation study using the XCAT2 phantom. Phys Med Biol 2016; 61:758-73. [PMID: 26732644 DOI: 10.1088/0031-9155/61/2/758] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The spill-in counts from neighbouring regions can significantly bias the quantification over small regions close to high activity extended sources. This effect can be a drawback for (18)F-based radiotracers positron emission tomography (PET) when quantitatively evaluating the bladder area for diseases such as prostate cancer. In this work, we use Monte Carlo simulations to investigate the impact of the spill-in counts from the bladder on the quantitative evaluation of prostate cancer when using (18)F-Fluorcholine (FCH) PET and we propose a novel reconstruction-based correction method. Monte Carlo simulations of a modified version of the XCAT2 anthropomorphic phantom with (18)F-FCH biological distribution, variable bladder uptake and inserted prostatic tumours were used in order to obtain simulated realistic (18)F-FCH data. We evaluated possible variations of the measured tumour Standardized Uptake Value (SUV) for different values of bladder uptake and propose a novel correction by appropriately adapting image reconstruction methodology. The correction is based on the introduction of physiological background terms on the reconstruction, removing the contribution of the bladder to the final image. The bladder is segmented from the reconstructed image and then forward-projected to the sinogram space. The resulting sinograms are used as background terms for the reconstruction. SUV max and SUV mean could be overestimated by 41% and 22% respectively due to the accumulation of radiotracer in the bladder, with strong dependence on bladder-to-lesion ratio. While the SUVs measured under these conditions are not reliable, images corrected using the proposed methodology provide better repeatability of SUVs, with biases below 6%. Results also showed remarkable improvements on visual detectability. The spill-in counts from the bladder can affect prostatic SUV measurements of (18)F-FCH images, which can be corrected to less than 6% using the proposed methodology, providing reliable SUV values even in the presence of high radioactivity accumulation in the bladder.
Collapse
Affiliation(s)
- Jesús Silva-Rodríguez
- L2A2, Faculty of Physics, University of Santiago de Compostela (USC). Edificio Monte da Condesa, Campus Vida s/n, 15782 Santiago de Compostela, Galicia, Spain. Molecular Imaging Group, Instituto de Investigación Sanitarias (IDIS). Travesía da Choupana s/n, 15706 Santiago de Compostela, Galicia, Spain. Division of Biomedical Imaging, University of Leeds. Worsley Building, LS2 9JT, Leeds, UK
| | | | | | | | | | | |
Collapse
|
20
|
Silva-Rodríguez J, Cortés J, Pardo-Montero J, Pérez-Fentes D, Herranz M, Ruibal Á, Aguiar P. In vivo quantification of renal function in mice using clinical gamma cameras. Phys Med 2015; 31:242-7. [PMID: 25726477 DOI: 10.1016/j.ejmp.2015.01.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2014] [Revised: 01/21/2015] [Accepted: 01/22/2015] [Indexed: 10/23/2022] Open
Abstract
INTRODUCTION In preclinical research, the growing number of transgenic models has led to the need for renal-function studies in mice. Many efforts have been made to develop dedicated SPECT systems for rodents, but their availability is limited due to high capital costs. The aim of this work is to demonstrate the feasibility of mouse renal imaging by using an inexpensive alternative based on clinical gamma-cameras. METHODS A healthy mouse was scanned 3 h after injection of 6 mCi of Dimercaptosuccinic acid (DMSA) labeled with 99mTc by using a single-head gamma-camera in conjunction with a dedicated pinhole collimator. List-mode data were binned to emulate multiple injections of 1 mCi, 0.1 mCi and 0.01 mCi of 99mTc-DMSA and 6-min ventral and dorsal planar images were acquired and SPECT imaging (60 projection images acquired over 60 min) was performed. An optimization of the protocols in terms of injected activity, time scan, renal cortex uniformity and cortex-to-pelvis contrast was carried out. RESULTS The appropriate protocols were an injected activity of 0.6 mCi, combined with duration of scanning of 1 min for planar and 60 min for SPECT imaging. Our results were validated through the relative quantification of renal function, which showed that both kidneys contributed equally to the total function. They showed that functional structures of the mouse kidneys can be visually distinguished as easily as in human studies. CONCLUSIONS Our findings showed the feasibility of conducting quantitative DMSA SPECT studies of anesthetized mice on clinical gamma cameras.
Collapse
Affiliation(s)
- Jesús Silva-Rodríguez
- L2A2, University of Santiago de Compostela, Santiago de Compostela, Spain; Molecular Imaging Group, IDIS Health Research Institute, Santiago de Compostela, Spain; Nuclear Medicine Dept, University Hospital of Santiago (CHUS), Santiago de Compostela, Spain
| | - Julia Cortés
- Molecular Imaging Group, IDIS Health Research Institute, Santiago de Compostela, Spain; Nuclear Medicine Dept, University Hospital of Santiago (CHUS), Santiago de Compostela, Spain
| | - Juan Pardo-Montero
- Molecular Imaging Group, IDIS Health Research Institute, Santiago de Compostela, Spain; Medical Physics Dept, University Hospital of Santiago (CHUS), Santiago de Compostela, Spain
| | - Daniel Pérez-Fentes
- Molecular Imaging Group, IDIS Health Research Institute, Santiago de Compostela, Spain; Urology Dept, University Hospital of Santiago (CHUS), Santiago de Compostela, Spain
| | - Michel Herranz
- Molecular Imaging Group, IDIS Health Research Institute, Santiago de Compostela, Spain; Nuclear Medicine Dept, University Hospital of Santiago (CHUS), Santiago de Compostela, Spain; Galaria Cyclotron Unit, Santiago de Compostela, Spain
| | - Álvaro Ruibal
- Molecular Imaging Group, IDIS Health Research Institute, Santiago de Compostela, Spain; Nuclear Medicine Dept, University Hospital of Santiago (CHUS), Santiago de Compostela, Spain; In-vivo Molecular Imaging Group, Dept. of Psychiatry, Radiology and Public Health, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | - Pablo Aguiar
- Molecular Imaging Group, IDIS Health Research Institute, Santiago de Compostela, Spain; Nuclear Medicine Dept, University Hospital of Santiago (CHUS), Santiago de Compostela, Spain; In-vivo Molecular Imaging Group, Dept. of Psychiatry, Radiology and Public Health, University of Santiago de Compostela (USC), Santiago de Compostela, Spain.
| |
Collapse
|
21
|
Ruibal Á, Aguiar P, Del Río MC, Nuñez MI, Pubul V, Herranz M. Cell membrane CD44v6 levels in squamous cell carcinoma of the lung: association with high cellular proliferation and high concentrations of EGFR and CD44v5. Int J Mol Sci 2015; 16:4372-8. [PMID: 25809603 PMCID: PMC4394425 DOI: 10.3390/ijms16034372] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Revised: 02/02/2015] [Accepted: 02/03/2015] [Indexed: 01/12/2023] Open
Abstract
Membranous CD44v6 levels in tumors and surrounding samples obtained from 94 patients with squamous cell lung carcinomas were studied and compared to clinical stage, cellular proliferation, membranous CD44v5 levels, epidermal growth factor receptor EGFR and cytoplasmatic concentrations of CYFRA 21.1. CD44v6 positive values were observed in 33/38 non-tumor samples and in 76/94 tumor samples, but there were not statistically significant differences between both subgroups. In CD44v6 positive tumor samples, CD44v6 was not associated with clinical stage, histological grade, ploidy and lymph node involvement, but significant association was found with high cellular proliferation. Likewise, CD44v6 positive tumors had significantly higher levels of EGFR and CD44v5. In patients with squamous cell lung carcinomas and clinical stage I, positive CD44v6 cases were associated with the same parameters. Furthermore, positive CD44v5 squamous tumors were associated significantly with histological grade III and lower levels of CYFRA21.1. Our findings support the value of CD44v6 as a possible indicator of poor outcome in patients with squamous lung carcinomas.
Collapse
Affiliation(s)
- Álvaro Ruibal
- Molecular Imaging Group, Faculty of Medicine, University of Santiago Compostela, R/de San Francisco, s/n., Santiago de Compostela 15782, Spain.
- Nuclear Medicine Department, University Hospital Santiago Compostela (CHUS), R/Choupana, s/n., Santiago de Compostela 15706, Spain.
- Fundación Tejerina, C/José Abascal, 40, Madrid 28003, Spain.
| | - Pablo Aguiar
- Molecular Imaging Group, Faculty of Medicine, University of Santiago Compostela, R/de San Francisco, s/n., Santiago de Compostela 15782, Spain.
- Nuclear Medicine Department, University Hospital Santiago Compostela (CHUS), R/Choupana, s/n., Santiago de Compostela 15706, Spain.
| | | | - Matilde Isabel Nuñez
- Nuclear Medicine Department, University Hospital Santiago Compostela (CHUS), R/Choupana, s/n., Santiago de Compostela 15706, Spain.
| | - Virginia Pubul
- Nuclear Medicine Department, University Hospital Santiago Compostela (CHUS), R/Choupana, s/n., Santiago de Compostela 15706, Spain.
| | - Michel Herranz
- Molecular Imaging Group, Faculty of Medicine, University of Santiago Compostela, R/de San Francisco, s/n., Santiago de Compostela 15782, Spain.
- Nuclear Medicine Department, University Hospital Santiago Compostela (CHUS), R/Choupana, s/n., Santiago de Compostela 15706, Spain.
| |
Collapse
|
22
|
Ruibal Á, Aguiar P, Del Rio MC, Arias JI, Menéndez-Rodríguez P, Gude F, Herranz M. Histological grade (HG) in invasive ductal carcinomas of the breast of less than 1 cm: clinical and biological associations during progression from HG1 to HG3. Anticancer Res 2015; 35:569-573. [PMID: 25550604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM To study the clinical and biological (cellular proliferation and hormone-dependence) associations during the progression of histological grade (HG), from HG1 to HG3, in invasive ductal carcinomas of the breast (IDC) <1 cm. PATIENTS AND METHODS The study group included 119 women with IDCs ≤1 cm, aged between 27 and 88 years (median=61 years). The parameters analyzed were: histological grade (HG1: 52; HG2: 45; HG3: 22); axillary lymph node involvement (N); distant metastasis (M); and immunohistochemical expression of estrogen (ER), progesterone (PR) and androgen (AR) receptors, and Ki67, p53 and B-cell lymphoma 2 (BCL2). RESULTS Compared to HG3 tumors, HG1s exhibited an increased expression of ER, AR and BCL2, as well as lower expression of p53 and Ki67. In HG1 tumors, significant (p<0.05) associations were found between ER and PR (positive), ER and p53 (negative), ER and Ki67 (negative), PR and AR (positive), PR and p53 (negative), AR and p53 (negative), p53 and BCL2 (negative), and between BCL2 and Ki67 (negative). HG3s only showed significant (p<0.05) associations between ER and Ki-67 (negative) and between BCL2 or Ki-67 (negative). Only two significant relationships (ER-Ki67 and BCL2-Ki67) persisted in all three grades. CONCLUSION Our results lead us to the following conclusions: i) compared HG1, HG3 ductal carcinomas exhibited decreased expression of ER, AR and BCL2 and increased expression of p53 and Ki67; and ii) only two significant and negative relations (ER-Ki67 and BCL2-Ki67) persisted in all three grades.
Collapse
Affiliation(s)
- Álvaro Ruibal
- Molecular Imaging Group, Nuclear Medicine Service, University Hospital of Santiago de Compostela, IDIS, Santiago de Compostela, Spain Molecular Imaging and Medical Physics Group, Faculty of Medicine, University of Santiago de Compostela (USC), Santiago de Compostela, Spain Tejerina Foundation, Madrid, Spain
| | - Pablo Aguiar
- Molecular Imaging Group, Nuclear Medicine Service, University Hospital of Santiago de Compostela, IDIS, Santiago de Compostela, Spain Molecular Imaging and Medical Physics Group, Faculty of Medicine, University of Santiago de Compostela (USC), Santiago de Compostela, Spain
| | | | | | | | - Francisco Gude
- Clinical Epidemiology Service, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
| | - Michel Herranz
- Molecular Imaging Group, Nuclear Medicine Service, University Hospital of Santiago de Compostela, IDIS, Santiago de Compostela, Spain Molecular Imaging Program, Galicia Radiopharmaceuticals Unit, GALARIA-SERGAS, Santiago de Compostela, Spain
| |
Collapse
|
23
|
Silva-Rodríguez J, Aguiar P, Domínguez-Prado I, Fierro P, Ruibal Á. Simulated FDG-PET studies for the assessment of SUV quantification methods. Rev Esp Med Nucl Imagen Mol 2014; 34:13-8. [PMID: 25107595 DOI: 10.1016/j.remn.2014.07.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Revised: 07/08/2014] [Accepted: 07/09/2014] [Indexed: 11/30/2022]
Abstract
AIM To study in detail the accuracy and repeatability of three commonly used methods for SUV estimation in solitary pulmonary nodules. MATERIAL AND METHODS We have designed a realistic framework based on simulated FDG-PET acquisitions from an anthropomorphic activity model that included solitary pulmonary nodules (different sizes) of well-known SUV. This framework enables us to compare the SUV values obtained from the reconstructed PET images with the real SUV values. Three commonly used methods (SUVmax, SUVmean and SUV50) were used to estimate the tumor activity. RESULTS Our results showed the tumor activity was overestimated using SUVmax and clearly subestimated using SUVmean. Instead, the quantification of SUV50 showed great agreement with the simulated tumor activity and only slight subestimation was found for very small lesions. On the other hand, SUVmean showed better performance than SUV50 in terms of repeatability, providing variabilities below 5% for all tumor sizes and for injected doses as low as 111 MBq. CONCLUSIONS Our findings showed that SUV50 provided better performance for estimating accurately tumor SUV values in pulmonary nodules, but SUVmean showed better results in terms of repeatability.
Collapse
Affiliation(s)
- J Silva-Rodríguez
- Grupo de Imaxe Molecular e Oncoloxía, Instituto de Investigación Sanitarias (IDIS), Travesía da Choupana S/N 15706, Santiago de Compostela, Galicia, Spain; L2A2-USC, Facultade de Física, Universidade de Santiago de Compostela, Praza do Obradoiro, s/n, 15782, Santiago de Compostela, A Coruña, Galicia, Spain
| | - P Aguiar
- Grupo de Imaxe Molecular e Oncoloxía, Instituto de Investigación Sanitarias (IDIS), Travesía da Choupana S/N 15706, Santiago de Compostela, Galicia, Spain; In Vivo Molecular Imaging Group (IMIG), Facultade de Medicina, Universidade de Santiago de Compostela, Praza do Obradoiro, s/n, 15782, Santiago de Compostela, A Coruña, Galicia, Spain.
| | - I Domínguez-Prado
- Servicio de Medicina Nuclear, Complexo Hospitalario Universitario de Santiago de Compostela, Travesía da Choupana S/N 15706, Santiago de Compostela, Galicia, Spain
| | - P Fierro
- Servicio de Medicina Nuclear, Complexo Hospitalario Universitario de Santiago de Compostela, Travesía da Choupana S/N 15706, Santiago de Compostela, Galicia, Spain
| | - Á Ruibal
- Grupo de Imaxe Molecular e Oncoloxía, Instituto de Investigación Sanitarias (IDIS), Travesía da Choupana S/N 15706, Santiago de Compostela, Galicia, Spain; In Vivo Molecular Imaging Group (IMIG), Facultade de Medicina, Universidade de Santiago de Compostela, Praza do Obradoiro, s/n, 15782, Santiago de Compostela, A Coruña, Galicia, Spain; Servicio de Medicina Nuclear, Complexo Hospitalario Universitario de Santiago de Compostela, Travesía da Choupana S/N 15706, Santiago de Compostela, Galicia, Spain; Fundación Tejerina, Calle de José Abascal 40, 28003 Madrid, Spain
| |
Collapse
|
24
|
Aguiar P, Pino F, Silva-Rodríguez J, Pavía J, Ros D, Ruibal Á, El Bitar Z. Analytical, experimental, and Monte Carlo system response matrix for pinhole SPECT reconstruction. Med Phys 2014; 41:032501. [DOI: 10.1118/1.4866380] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
25
|
Salas A, Vega A, Milne RL, García-Magariños M, Ruibal Á, Benítez J, Carracedo Á. The ‘Pokemon’ ( ZBTB7) Gene: No Evidence of Association with Sporadic Breast Cancer. Clin Med Oncol 2008; 2:357-62. [PMID: 21892298 PMCID: PMC3161631 DOI: 10.4137/cmo.s569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
It has been proposed that the excess of familiar risk associated with breast cancer could be explained by the cumulative effect of multiple weakly predisposing alleles. The transcriptional repressor FBI1, also known as Pokemon, has recently been identified as a critical factor in oncogenesis. This protein is encoded by the ZBTB7 gene. Here we aimed to determine whether polymorphisms in ZBTB7 are associated with breast cancer risk in a sample of cases and controls collected in hospitals from North and Central Spanish patients. We genotyped 15 SNPs in ZBTB7, including the flanking regions, with an average coverage of 1 SNP/2.4 Kb, in 360 sporadic breast cancer cases and 402 controls. Comparison of allele, genotype and haplotype frequencies between cases and controls did not reveal associations using Pearson’s chi-square test and a permutation procedure to correct for multiple test. In this, the first study of the ZBTB7 gene in relation to, sporadic breast cancer, we found no evidence of an association.
Collapse
Affiliation(s)
- Antonio Salas
- Unidade de Xenética, Instituto de Medicina Legal, Facultad de Medicina, Universidad de Santiago de Compostela, 15782, Galicia, Spain
- Grupo de Medicina Xenómica, CIBERER, Universidad de Santiago de Compostela, Galicia, Spain
| | - Ana Vega
- Grupo de Medicina Xenómica, CIBERER, Universidad de Santiago de Compostela, Galicia, Spain
- Fundación Pública Galega de Medicina Xenómica (FPGMX)-Consellería de Sanidad Santiago de Compostela, 15706, Galicia, Spain
| | - Roger L. Milne
- Centro Nacional de Genotipado (CeGen), Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
| | | | - Álvaro Ruibal
- Servicio de Medicina Nuclear, Hospital Clínico Universitario, Santiago
| | - Javier Benítez
- Centro Nacional de Genotipado (CeGen), Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
- Programa de Genética del Cáncer Humano, CIBERER, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
| | - Ángel Carracedo
- Unidade de Xenética, Instituto de Medicina Legal, Facultad de Medicina, Universidad de Santiago de Compostela, 15782, Galicia, Spain
- Grupo de Medicina Xenómica, CIBERER, Universidad de Santiago de Compostela, Galicia, Spain
- Fundación Pública Galega de Medicina Xenómica (FPGMX)-Consellería de Sanidad Santiago de Compostela, 15706, Galicia, Spain
| |
Collapse
|
26
|
Peña C, Jaquet M, Salgado J, Pubul V, Ruibal Á, Vázquez B. Perfusión pulmonar asimétrica como causa de edema agudo de pulmón unilateral complicando un infarto agudo de miocardio. Rev Esp Cardiol 2005. [DOI: 10.1157/13077241] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
27
|
Ruibal Á, Núñez MI, Rodríguez J. Expresión de la molécula de adhesión CD44 estándar (CD44s) en el carcinoma escamoso de pulmón. Med Clin (Barc) 2004. [DOI: 10.1157/13058174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|